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Background: Interleukin 15 (IL-15) is a pro-inﬂammatory cytokine involved in inﬂammatory diseases and
IL-15 is expressed in atherosclerotic plaques.
Methods: To establish the role of IL-15 in atherosclerosis we studied the effect of IL-15 on atherosclerosis
associated cells in vitro and in vivo by neutralizing IL-15 using a DNA vaccination strategy.
Results: Upon feeding a Western type diet LDLr−/− mice do express higher levels of IL-15 within the
spleen and the number of IL-15 expressing cells among blood leukocytes and spleen cells is increased.
Additionof IL-15 tomacrophages induces theexpressionTNF-andCCL-2.After themicewerevaccinated
against IL-15, we observe a reduction in plaque size of 75% plaque. Unexpectedly, the relative number
of macrophages within the plaque was 2-fold higher in IL-15 vaccinated mice than in control mice.therosclerosis
nﬂammation
ouse model
Vaccination against IL-15 leads to an increased cytotoxicity against IL-15 overexpressing target cells,
resulting in a reduction in IL-15 expressing cells and macrophages in blood and spleen and a decreased
CD4/CD8 ratio.
Conclusion: Hypercholesterolemia leads to upregulation of IL-15 within spleen and blood. DNA vaccina-
tion against IL-15doesmarkedly reduces atherosclerotic lesion size, but does not promote lesion stability.. Introduction
Atherosclerosis is characterized as a dyslipidemic induced
hronic inﬂammatory disease of the arterial wall [1]. During the
arious stages of lesion development, monocytes and T cells are
ecruited to the arterial wall [2], already in the early stages of
therogenesis, macrophages and T cells are present in the intima
f the atherosclerotic plaque [3]. Interleukin 15 (IL-15) is a pro-
nﬂammatory cytokine which is expressed by different immune
ells such as monocytes and macrophages and promotes T cell
roliferation independently of antigen-speciﬁc T cell receptor acti-
ation [4]. IL-15 is also expressed in a biologically active form on
he surface of monocytes and activated macrophages. This surface
xpressed IL-15 is approximately 5 times more effective than solu-
le IL-15 in the induction of T cell proliferation [5]. IL-15 expression
s associated with chronic inﬂammatory diseases such as rheuma-
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toid arthritis [6]. In addition, IL-15 is found to be expressed in
human and murine atherosclerotic lesions [7,8] and may therefore
affect T cells within the plaque.
The IL-15 receptor shares two subunits, the  and c subunit,
with the IL-2 receptor,while the third subunit is formedbyaunique
-chain, IL-15R [9]. Because the IL-15 and IL-2 receptor share
two subunits, IL-15 shares biological activities with IL-2, such as
the induction of proliferation of T cell subsets. There are however
opposing effects of IL-2 and IL-15. IL-2 is primarily involved in the
maintenance of regulatory T cells and IL-15 plays mainly a role in
the survival of T cells and thus in memory cell formation [10–12].
IL-15 not only activates T cells, it is also a strong chemoattrac-
tant for T cells and Natural killer (NK) cells [13,14] and enhances
CD44 mediated T cell adhesion to endothelial cells [15]. IL-15 is
also involved in expansion and survival of Natural killer T (NKT)
cells, which form an important link between the innate and adap-
tive immune response and enhance atherosclerosis [16]. IL-15
Open access under the Elsevier OA license.ﬁnally exerts an autocrine regulation of the production of pro-
inﬂammatory cytokines by macrophages, such as TNF-, IL-6 and
IL-1 [17].
We studied the role of IL-15 in atherosclerotic lesion forma-
tion by applying an in vivo blockade of IL-15 using oral vaccination,
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hich resulted in a 75% reduction in lesion size with a concomitant
ncrease inmacrophage content of the plaque, thereby establishing
n important role for IL-15 in atherogenesis.
. Methods
.1. Animals, materials, bacterial strains and cell lines
All animal work was approved by Leiden University and was in
ompliance with the Dutch government guidelines. LDL receptor
eﬁcient (LDLr−/−) mice were purchased from Jackson Laborato-
ies. The mice were kept under standard laboratory conditions and
ood and water were provided ad libitum. Recombinant murine
L-15 was purchased from PeproTech, biotinylated polyclonal
ouse anti-IL-15 was obtained from R&D systems. The attenuated
almonella typhimurium (Dam-;AroA-,strain:SL7207)was provided
y Dr. Kriszitana M. Zsebo (Remedyne Corporation, Santa-Barbara,
A). The macrophage cell line(RAW246.7), the endothelial cell
ine(H5V) and mouse ﬁbroblasts were cultured in DMEM with 10%
CS, 2mmol/L glutamin, 0.1U/L penicillin, and 100mg/L strepto-
ycin. Vascular smooth muscle cells were isolated from a murine
orta and cultured as described previously [18].
.2. In vitro assessment of IL-15
Cells were added to a 24-well plate (2.5×105 RAWcells/mL,
.0×105 cells for H5V and vSMC). Where stated, 100ng/ml recom-
inant IL-15 was added to the culturing medium and culturing
edium alone served as a control. Cells were incubated for 24h,
nd thereafter the cells were used for qPCR and the supernatant
as used for ELISA. All experiments were performed in triplicate.
.3. RNA isolation and qPCR
Total RNA was isolated using Trizol (Boehringer Mannheim)
nd reverse transcribed (RevertAidPTMP M-MuLV reverse transcrip-
ase, Fermentas). qPCR was analyzed with SYBRgreen mastermix
PerkinElmer) and a ﬁnal concentration of 300nM primers
Table 1), using acidic ribosomal phosphoproteinP0(36B4) as an
nternal standard.
.4. ELISA
A mouse TNF- set (PharMingen) was used to detect TNF- in
ulture supernatant according to manufacturers’ protocol.
.5. Construction of the DNA vaccine
Murine IL-15 (AI503618) was cloned into the eukaryotic
xpression plasmid pcDNA3.1 (Invitrogen). The 605bp. fragment
ncoding the entire IL-15 gene was ampliﬁed using PCR primers:
′-GAAGCCCATCGCCATAGC-3′ and 5′-GAGCAGCAGGTGGAGGTA-
′ and subsequent cloned into pcDNA3.1 with EcoRV, generating
cDNA3.1-IL-15. Subsequently, S. typhimurium was electroporated
ith pcDNA3.1-IL-15 or an empty pcDNA3.1 plasmid [19].
.6. Vaccination and the induction of atherosclerosis
Mice were vaccinated prior to the induction of atherosclero-
is with 108 cfu S. typhimurium transformed with empty pcDNA3.1
control) or pcDNA3.1-IL-15 as previously described [19]. Male
DLr−/− mice 10–12 weeks of age were fed a Western-type diet
ontaining 15% cocoa butter and 0.25% cholesterol 2 weeks prior to
ollar placement. Atherosclerosiswas induced by placement of col-
ars (0.3mm, Dow Corning, Midland, Michigan) around the carotid
rteries as previously described [20]. Hereafter, the mice were fed9 (2011) 976–983 977
a Western-type diet for 8 more weeks. Total cholesterol levels dur-
ing the experiment were quantiﬁed spectrophotometrically using
an enzymatic procedure (Roche Diagnostics, Germany). Precipath
standardized serum (Boehringer, Germany)was used as an internal
standard.
2.7. Cytotoxicity assay
The murine ﬁbroblast cells were used as target cells and were
co-transfected with pcDNA3.1-IL-15 and pcDNA3.1-eGFP using
ExGen500 (Fermentas, Germany) according to the manufacturer’s
protocol. 24h after transfection, 106 spleen cells isolated from IL-
15 vaccinated or control vaccinated mice were added to the target
cells. 24h later, cells were ﬁxed using FormalFixx (3.7%, Thermo
Shandon, Pittsburgh, PA), and the number of GFP-ﬂuorescent cells
per well was determined.
2.8. Histology and immunohistochemistry
Carotid arteries were removed for analysis as described by Von
der Thüsen et al. [20]. The arteries were embedded in OCT com-
pound (TissueTek; Sakura Finetek, The Netherlands). Cryosections
of 5m were made proximally of the collar occlusion and stained
with hematoxylin (Sigma Diagnostics, MO) and eosin (Merck Diag-
nostica, Germany). Corresponding sections on separate slides were
stained immunohistochemically for macrophages using an anti-
body against a macrophage-speciﬁc antigen (MoMa-2, Research
Diagnostics Inc.). Quantiﬁcation of the staining was performed by
using a Leica DM-RE microscope and Leica Qwin Imaging software
(Leica Ltd., Germany).
2.9. FACS analysis of leukocytes
Peripheral Blood Mononuclear Cells (PBMC) were isolated
after orbital bleeding using Lympholyte (Cedarlane, Canada) as
described in the manufacture’s protocol. Spleens were dissected
and single cell suspension was obtained by passing the spleen
througha70mcell strainer (Falcon, TheNetherlands). Leukocytes
were puriﬁed using Lympholyte. Cells were stained with FITC-
conjugated anti-mouse CD8 (0.125g/sample, Pharmingen) and
PE-conjugated anti-mouse CD69 (0.125g/sample, eBioscience).
For the staining of surface bound IL-15, the leukocytes were
stained with biotinylated anti-mouse IL-15 (R&D systems) and
PE-conjugatedstreptavidin (BDPharmingen)andanalyzedbyﬂow-
cytometry on a FACSCalibur. All data was analyzed with CELLQuest
software (BD Bioscience, The Netherlands).
2.10. Statistical analysis
All data are expressed asmeans± SEM. The two-tailed student’s
t-testwas used to compare individual groups ofmice or cells.When
indicated, a Mann–Whitney test was used to analyze not normally
distributed data. P values of <0.05 were considered signiﬁcant.
3. Results
3.1. IL-15 is upregulated in hypercholesterolemic mice
The spleens of LDLr−/− mice were collected at different time
points after the start of the Western-type diet feeding and mRNA
expression of IL-15 was quantiﬁed. The expression of IL-15 mRNA
was signiﬁcantly elevated in the spleen at 6 weeks after the start
of the diet (Fig. 1A). Since IL-15 expression is also regulated at a
post-translational level and is mainly membrane bound [5], we
also determined the cell surface expression of IL-15. Spleen cells
and PBMCs were isolated from LDLr−/− mice which were fed a
978 T. van Es et al. / Vaccine 29 (2011) 976–983
Table 1
Primer sequences for quantitative PCR.
Gene GenBank acession # Forward primer 5′ →3′ Reverse primer 5′ →3′ Amplicon size bp
IL-15 NM 008357 TGAGGCTGGCATTCATGTCTT ATCTATCCAGTTGGCCTCTGTTTT 75 546–621
IL-1ß NM 008361 TGGTGTGTGACGTTCCCATTA AGGTGGAGAGCTTTCAGCTCATAT 102 341–443
IL-10 M37897 TCTTACTGACTGGCATGAGGATCA GTCCGCAGCTCTAGGAGCAT 105 107–212
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CCL2 M19681 GCATCTGCCCTAAGGTCTTCA
CCR2 MMU51717 CCTTGGGAATGAGTAACTGTGTGA
36B4 NM 007475 GGACCCGAGAAGACCTCCTT
estern diet or a normal Chow diet for 10 weeks. FACS analysis
howed that the percentage of IL-15 expressing cells within the
pleen and PBMCs was highly elevated after 10 weeks of Western
ype diet (Fig. 1B; 12.59±0.65% versus 26.07±3.44%, P<0.05 and
.28±0.06% versus 4.95±0.98%, P<0.05, respectively).
.2. IL-15 predominately affects macrophages in vitro
Wedetermined the effect of IL-15 on cell lines that represent the
ain cell types in the atherosclerotic lesion; macrophages (RAW
ells), vascular smooth muscle cells (vSMCs) and endothelial cells
H5V cells). The relative expression is highest for macrophages
Fig. 2A), while also for vSMCs and endothelial cells a distinct
xpression is found. Addition of recombinant IL-15 to the various
ell types induced only in macrophages an increased expression
f tumor necrosis factor (TNF)- on protein level (Fig. 2B). In line
ith the increase in TNF-alpha, we observed in macrophages a dis-
inct increase in the pro-inﬂammatory cytokine IL-1, whereas
here was no signiﬁcant effect seen on mRNA encoding IL-10
Fig. 2C), IFN- or IL-12 (p40) (data not shown). In addition, IL-
5 signiﬁcantly induced the expression of CXCL1, CCL2 and CCR2 in
acrophages (Fig. 2D). These results indicate that IL-15 may affect
he chemokines induced migration of macrophages [21]. Endothe-
ial cells did not respond to IL-15 by upregulation of CXCL1, CCL2 or
CR2 on mRNA levels. In addition, IL-15 did not affect the expres-
ion of adhesion molecules such as VCAM-1, ICAM-1, PECAM and
-selectin in endothelial cells (data not shown).
.3. Vaccination against IL-15 induces an IL-15 speciﬁc cytotoxic
cell response
The Western-diet induced IL-15 expression on spleen cells and
BMCs and the IL-15 mediated activation of macrophage stimu-
ated us to analyze the effect of IL-15 blockade via vaccination. To
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ype diet (A). PBMCs and spleen cells were isolated and stained for surface bound IL-15(
eeks of Western type diet (white bars, N=5) and after 10 weeks of Western type diet (bCCTGAGGGCAACACCTTCAA 95 73–168
TTCACTGTCACACTGGTCACTCCTA 127 398–525
TGGAGAGATACCTTCGGAACTTCT 140 942–1082
GCACATCACTCAGAATTTCAATGG 85 464–548
this end, LDLr−/− mice were vaccinated against IL-15 by oral deliv-
ery using an attenuated strain of S. typhimurium transformed with
an IL-15expressionvector (pcDNA3.1-IL-15)orwithS. typhimurium
transformed with an empty vector (pcDNA3.1) as a control. This
vaccination strategy leads to the induction of CD8+ cytotoxic T
cells that speciﬁcally lyse those cells that overexpress IL-15 and
present IL-15 peptides via MHC-I [19]. This protocol was used to
study the role of VEGFR2 and CD99 in atherosclerosis [22,23]. Fol-
lowing vaccination, mice were fed a Western-type diet for 2 weeks
and collars were placed around the carotid arteries which results
in ﬂow-induced atherosclerotic lesion formation [20]. A Subse-
quent to vaccination, we established the activation state of the
CD8+ T cell population. Spleen cells were isolated and stained for
CD8 and CD69, an early T cell activation marker, and the percent-
age of CD8+CD69+ double positive cells was signiﬁcantly increased
uponvaccination against IL-15 compared to the control vaccination
(Fig. 3A; 16.0±2.1% versus 10.4±0.1%, P<0.05). In order to study
the speciﬁcity of CD8+ cytotoxic T cells, spleen cells fromvaccinated
and control mice were co-cultured with murine ﬁbroblasts that
were co-transfected with pcDNA3.1-IL-15 and pcDNA3.1-GFP. The
number of surviving IL-15 expressing target cells was determined
by counting GFP positive cells. The number of IL-15 expressing tar-
get cells was reduced by 50% after incubation with spleen cells
from IL-15 vaccinated mice, whereas spleen cells from control
vaccinated mice, did not signiﬁcantly lyse IL-15 expressing cells
(Fig. 3B; 49±1% in vaccinated group versus 81±4% in control
group, P<0.01).
3.4. Vaccination against IL-15 reduces atherosclerotic lesion size
in hypercholesterolemic LDLr−/− mice
Atherosclerosis was determined in control and IL-15 vaccinated
mice 6 weeks after collar placement. IL-15 vaccination did not
affect plasma cholesterol levels during the experiment (Fig. 3C).
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wig. 2. Effect of IL-15 on gene expression in plaque related cell types. IL-15 expressio
hite) was added to different cell types. Cellular activation was measured by TNF-
f 100ng/mL IL-15 (black), or without IL-15 (white) for inﬂammatory genes (C) and
uantiﬁcation of Hematoxylin–Eosin (HE) stained atherosclerotic
laques showed that vaccination against IL-15 resulted in a 75%
ecrease in lesion size as compared to the control group (Fig. 4A–C;
3722±3116m2 versus 53977±15332m2, P<0.05). Immuno-
istochemical staining for macrophages showed a signiﬁcant
hange in plaque composition (Fig. 4F). The relative number of
acrophages per plaque area was 2-fold higher in IL-15 vacci-
ated mice (Fig. 4E) than that in control vaccinated mice (Fig. 4D),
ndicative for a less advanced state of the lesions in the vaccinated
ice.
.5. Surface expression of IL-15 and CD4/CD8 ratio is reduced
fter vaccination
As hypercholesterolemia induced surface expression of IL-15 on
BMCsandspleencells (Fig. 1B)weevaluated theeffectof IL-15vac-
ination on the percentage of IL-15 positive cells within the spleen
nd PBMCs. Spleen cells and PBMCs were stained for IL-15 and for
he macrophage marker F4/80 and analyzed by FACS. Upon IL-15
accination, the surface expression of IL-15 on spleen cells was
lmost completely reduced to a level comparable to that deter-
ined in mice before the start of the Western-type diet (Fig. 5A,
< 0.05).Within the PBMCpopulation IL-15 surface expressionwas
lso decreased (Fig. 5A, P<0.05). Within the macrophage popula-
ion we observed an almost 70% reduction in the percentage of
L-15 positive macrophages (Fig. 5B, P<0.01), while the CD4/CD8
atio in blood, indicative of the inﬂammatoruy status of the mice,
as 3-fold lower in the IL-15 vaccinated mice (Fig. 5, P<0.01).determined in RAWcells, H5V cells and vSMC (A). IL-15 (black) or no IL-15 (control;
ase (B). The expression of several genes was measured in RAW cells after addition
otaxic associated genes (D). *P<0.05, **P<0.01 and ***P<0.001
4. Discussion
Atherosclerosis is considered a dyslipidemia-induced chronic
inﬂammatory disease of the arterial wall. During atherosclerotic
lesion formation, monocytes and subsequently T cells inﬁltrate the
arterial wall [1]. DNA vaccination against IL-15 leads in LDLr−/−
mice to a blocked atherosclerotic lesion development, indicating
that IL-15 accelerates lesion formation.
Upon the start of a hypercholesterolemic diet in LDLr−/− mice
the mRNA expression of IL-15 is increased within the spleen. Fur-
thermore, hypercholesterolemia does increase the percentage of
IL-15 expressing cells in both blood and in spleen. These ﬁnd-
ings point to a possible relation between IL-15 expression and the
induction of atherosclerosis. IL-15 appears to be highly expressed
by macrophages and to a lesser extend by endothelial cells and
vSMCs. After stimulation of macrophages with IL-15, the mRNA
level of several pro-inﬂammatory cytokines, such as TNF- and IL-
1 are upregulated, while the secretion of TNF- is increased by
IL-15. Important proteins in the chemoattraction of macrophages,
CXCL1, CCL2 and CCR2, are also upregulated after incubation with
IL-15. These latter effects are also seen on human monocytes when
stimulated with IL-15 [24].
Vaccination against IL-15 was accomplished by oral adminis-
tration of a live attenuated S. typhimurium bacteria, transformed
with an eukaryotic expression vector encoding IL-15. This vacci-
nation method induces a strong, IL-15 speciﬁc, cytotoxic immune
response, resulting in the killing of cells overexpressing IL-15.
This is a similar mechanism as achieved by the oral vaccina-
tion against FLK-1 as described by Niethammer et al. [19] and
by Hauer et al. [22] and vaccination against CD99 described by
980 T. van Es et al. / Vaccine 29 (2011) 976–983
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an Wanrooij et al. [23]. These vaccination procedures resulted in
cytotoxic T cell-mediated killing of cells expressing FLK-1 and
D99, respectively. The reduction in IL-15 expressing cells within
he spleen and blood upon vaccination was accompanied by a 75%
eduction in atherosclerotic lesion size. During the experiment no
ifference was detected in total serum cholesterol levels between
he groups, indicating that IL-15 does not affect lipid-metabolism
nd the reduction in plaque is more likely due to changes in the
nﬂammatory status of the mice, similar to previous studies in
hich lowering the inﬂammatory status reduced atherosclerosis
ithout affecting cholesterol levels [29]. The reduced plaque size
as accompanied by a two-fold increase in the relative amount
f macrophages. As macrophage inﬁltration is a feature of early
ascular lesion formation [25], it may be speculated that plaque
ormation and progression is strongly retarded but not prevented
ue to the blocking of IL-15. In addition, it is clear that the smallere) at the indicated times and total cholesterol level was determined in serum (C,
lesion tat develops upon IL-15 vaccination is more vulnerable since
the macrophage content is higher and the increased plaque insta-
bility after IL-15 vaccination is in contrast to previous experiments
of our group which in IL-12 vaccination both reduced the plaque
size and improved the stability of the plaque [29].
Although, IL-15 is involved in the expression of important
chemoattractants for macrophages it is likely that there are
additional sources for these chemokines within the plaque, for
example endothelial cells or vSMCs. We can also speculate that
the recruited macrophages within the plaque do not, or to a lesser
extent, express IL-15/IL15R as is demonstrated by the reduc-
tion of the surface expression of IL-15 on cells within spleen and
PBMCs. Macrophages express IL-15/IL15R complexes on their
surface upon activation and are able to activate T cells in an
antigen-independent way. Membrane bound IL-15 is not only 5-
times more effective in inducing T cell proliferation than soluble
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17,26]. Macrophages which lack IL-15/IL15R complex on the
urface are not able to sustain a full immune response within
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We suggest that the development of the lesion is arrested in
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0.05
the increased number of macrophages in the vessel wall and the
smaller lesion size, since mainly the innate immune response is
activated and adaptive immune response is likely impaired. How-
ever, IL-15 expressing cells are activated inﬂammatory cells, which
are also able to express other inﬂammatory mediators. Therefore
it should be taken into account that the effect we observe may
also be due to the absence of other mediators. The vaccination
method used in this study may lead to the initiation of new ther-
apies, which block the action of IL-15. There are some promising
results with phase I/II clinical trails with an anti-IL-15 antibody
treatment in patients with rheumatoid arthritis [27], which might
be extended to cardiovascular patients. Furthermore Gokkusu et al.
[28], recently demonstrated that genetic variation in IL-15gene and
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he importance of IL-15 signaling in atherosclerosis.
The vaccination strategyused in this study successfully evoked a
hemotoxic response targeting IL-15 expressing cells. This resulted
n a vast reduction in atherosclerosis, thereby providing new
nsights in the process of atherosclerosis and the contribution of IL-
5 in this process. These new insights may contribute to the future
mmunomodulating treatment of patients with cardiovascular dis-
ases.
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